Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPP 204106

Next Previous
Search
Drug Profile

IPP 204106

Alternative Names: IPP-204106; IPP204106N; Nucant programme IPP-204106; polyplexed Nucant; poyplexed IPP-204106

Latest Information Update: 04 Oct 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS
  • Developer CNRS; ImmuPharma
  • Class Antineoplastics; Eye disorder therapies; Peptides; Skin disorder therapies
  • Mechanism of Action Nucleolin inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Age-related macular degeneration; Diabetic retinopathy; Psoriasis; Wounds

Most Recent Events

  • 25 Sep 2018 Incanthera signs Heads of Terms on a prospective licensing agreement with ImmuPharma for IPP 204106 for treatment of Cancer
  • 28 Jan 2018 No recent reports of development identified for research development in Age-related-macular-degeneration in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in France (Parenteral, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top